ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
68,054.17
0.49%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
02/06/202411:40PR Newswire (US)GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
02/06/202411:30GlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
02/06/202411:30GlobeNewswire Inc.Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®TG:2GHMerus NV
02/06/202411:30Business WireCatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
02/06/202411:30GlobeNewswire Inc.Merus präsentiert Zwischenergebnisse zu MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab auf der ASCO®-Jahrestagung 2024TG:2GHMerus NV
02/06/202411:30PR Newswire (US)Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
02/06/202411:25PR Newswire (Canada)Avis aux médias - Agents de la paix en services correctionnels - Le TSO : pas juste dans la santé qu'il y en a
02/06/202411:23CointelegraphBitcoin bull flag joins MACD to tease new BTC price all-time high nextCOIN:BTCUSDBitcoin
02/06/202411:09Business WireStronger Than Ever: Adani Portfolio Delivers Record Performance
02/06/202410:32PR Newswire (US)Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
02/06/202410:31GlobeNewswire Inc.KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
02/06/202410:27GlobeNewswire Inc.Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
02/06/202410:24PR Newswire (US)Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
02/06/202410:13PR Newswire (US)LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
02/06/202410:00PR Newswire (US)WafaTech Unveils Comprehensive Suite of Cloud, Connectivity, and ICT Solutions for Saudi Arabia
02/06/202410:00PR Newswire (US)Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
02/06/202409:56Business WireBelantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myelomaNYSE:GSKGSK plc
02/06/202409:55GlobeNewswire Inc.Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection StudyNASDAQ:SEERSeer Inc
02/06/202409:45PR Newswire (US)ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
02/06/202409:30The Daily HodlOverlooked Indicator Hinting at ‘Stealth’ Bitcoin (BTC) Rallies to Fresh New All-Time Highs: Jason PizzinoCOIN:FETUSDFetch
02/06/202409:30PR Newswire (Canada)En pleine négociation, les intervenantes en petite enfance de la FIPEQ-CSQ sont solidaires de l'organisme Ma place au travail
02/06/202409:25PR Newswire (US)ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
02/06/202409:01Business WirePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)NASDAQ:PBYIPuma Biotechnology Inc
02/06/202409:00GlobeNewswire Inc.Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
02/06/202409:00GlobeNewswire Inc.ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerNASDAQ:ALXOALX Oncology Holdings Inc
02/06/202409:00PR Newswire (Canada)Adoption à l'unanimité du projet de loi no 56 - Un troisième jalon de la réforme du droit de la famille : pour protéger les enfants naissant hors mariage
02/06/202409:00PR Newswire (US)MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
02/06/202409:00PR Newswire (US)Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
02/06/202408:47PR Newswire (US)Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
02/06/202408:30Business WireTempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Su Consulta Reciente

BIT
AED
Aedes SIIQ
BIT
P1H560
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados